HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Somatostatin receptor imaging for neuroendocrine tumors.

Abstract
Tumors and metastases that express the somatostatin receptor subtypes sst2 sst3 or sst5 can be visualized in vivo after injection of radiolabeled octapeptide somatostatin analogs, like (111)In-pentetreotide. (111)In-pentetreotide scintigraphy also allows for more accurate staging of the disease by demonstrating tumor sites, which were not shown by conventional imaging. (111)In-pentetreotide scintigraphy may also detect resectable tumors that would have remained unrecognized using conventional radiological imaging techniques; it may prevent surgery with curative intent in those patients whose tumors have metastasized to a greater extend than could be detected with conventional radiological imaging and it may be used to select patients for treatment with the currently available octapeptide somatostatin analogs or with tumor targeted radioactive treatment with radiolabelled somatostatin analogs. (111)In-pentetreotide scintigraphy has also been used to select patients with pituitary tumors for medical treatment with octapeptide analogs, but its clinical usefulness for this purpose seems to be limited. It further allows scar tissue to be differentiated from tumor recurrence after the pituitary surgery or radiotherapy. However, a large variety of lesions in and around the pituitary region also express somatostatin receptors and, therefore, can be visualized by (111)In-pentetreotide scintigraphy.
AuthorsWouter W de Herder, Dik J Kwekkeboom, Richard A Feelders, Maarten O van Aken, Steven W J Lamberts, Aart-Jan van der Lely, Eric P Krenning
JournalPituitary (Pituitary) Vol. 9 Issue 3 Pg. 243-8 ( 2006) ISSN: 1573-7403 [Electronic] United States
PMID17001462 (Publication Type: Journal Article, Review)
Chemical References
  • Radiopharmaceuticals
  • Receptors, Somatostatin
  • Somatostatin
  • pentetreotide
Topics
  • Adrenal Gland Neoplasms (chemistry, radionuclide imaging)
  • Aged
  • Animals
  • Carcinoid Tumor (chemistry, radionuclide imaging)
  • Carcinoma, Medullary (chemistry, radionuclide imaging)
  • Gastrointestinal Neoplasms (chemistry, radionuclide imaging)
  • Humans
  • Magnetic Resonance Imaging
  • Neuroendocrine Tumors (chemistry, pathology, radionuclide imaging, therapy)
  • Pancreatic Neoplasms (chemistry, radionuclide imaging)
  • Pheochromocytoma (chemistry, radionuclide imaging)
  • Pituitary Neoplasms (chemistry, radionuclide imaging)
  • Predictive Value of Tests
  • Radiopharmaceuticals
  • Receptors, Somatostatin (analysis)
  • Somatostatin (analogs & derivatives)
  • Thyroid Neoplasms (chemistry, radionuclide imaging)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: